REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment
出版年份 2023 全文链接
标题
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 24, Issue 5, Pages e219-e227
出版商
Elsevier BV
发表日期
2023-05-03
DOI
10.1016/s1470-2045(23)00095-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Improving access to immunotherapy in low- and middle-income countries
- (2022) A. Patel et al. ANNALS OF ONCOLOGY
- Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpoint
- (2022) Laurens Manning et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- SCI : A Bayesian adaptive phase I/ II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials
- (2022) Yifei Zhang et al. PHARMACEUTICAL STATISTICS
- Financial toxicity of cancer care in low- and middle-income countries: a systematic review and meta-analysis
- (2022) Andrew Donkor et al. SUPPORTIVE CARE IN CANCER
- Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
- (2022) Nicholas A. Turner et al. Trials
- Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
- (2022) Cameron R Wolfe et al. Lancet Respiratory Medicine
- Transition of the PD‑1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re‑challenge
- (2022) Taku Nose et al. Molecular and Clinical Oncology
- A non-inferiority randomized phase III trial of standard immunotherapy versusreduced dose intensity in responding patients with metastatic cancer: MOIO study.
- (2022) Gwenaelle Gravis et al. JOURNAL OF CLINICAL ONCOLOGY
- 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
- (2022) G. Zalcman et al. ANNALS OF ONCOLOGY
- Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
- (2021) Jia Li Low et al. INTERNATIONAL JOURNAL OF CANCER
- Considerations for treatment duration in responders to immune checkpoint inhibitors
- (2021) Thomas U Marron et al. Journal for ImmunoTherapy of Cancer
- Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
- (2021) E. E. A. P. Mulder et al. BMC CANCER
- Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
- (2021) J. Randall Patrinely et al. JAMA Oncology
- The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
- (2021) Oliver Coen et al. BMC CANCER
- Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
- (2021) Mark J. Ratain et al. JOURNAL OF CLINICAL ONCOLOGY
- Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
- (2021) Adam Fundytus et al. LANCET ONCOLOGY
- Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
- (2021) Giacomo Oliveira et al. NATURE
- The Drug-Dosing Conundrum in Oncology — When Less Is More
- (2021) Mirat Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
- (2020) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Is it time to nationalise the pharmaceutical industry?
- (2020) Mariana Mazzucato et al. BMJ-British Medical Journal
- The cost of cancer in Europe 2018
- (2020) Thomas Hofmarcher et al. EUROPEAN JOURNAL OF CANCER
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2020) Shirish Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
- (2020) Kartik Sehgal et al. Clinical Lung Cancer
- The DURATIONS randomised trial design: Estimation targets, analysis methods and operating characteristics
- (2020) Matteo Quartagno et al. Clinical Trials
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
- (2019) Daan P. Hurkmans et al. Journal for ImmunoTherapy of Cancer
- Immuno-oncology drug development goes global
- (2019) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- (2019) Yanhong Zhou et al. STATISTICS IN MEDICINE
- Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
- (2018) David Turner et al. CLINICAL CANCER RESEARCH
- Rethinking non-inferiority: a practical trial design for optimising treatment duration
- (2018) Matteo Quartagno et al. Clinical Trials
- Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
- (2018) Russell Z. Szmulewitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
- (2018) Timothy J Iveson et al. LANCET ONCOLOGY
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.
- (2018) Tara D. Baetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Time Is Money: Optimizing the Scheduling of Nivolumab
- (2018) Mark J. Ratain et al. JOURNAL OF CLINICAL ONCOLOGY
- ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2017) Byoung Chul Cho et al. Journal of Thoracic Oncology
- Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
- (2017) Charlotte E Coles et al. LANCET
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Overspending driven by oversized single dose vials of cancer drugs
- (2016) Peter B Bach et al. BMJ-British Medical Journal
- Overspending driven by oversized single dose vials of cancer drugs
- (2016) Peter B Bach et al. BMJ-British Medical Journal
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- DOOR/RADAR: A Gateway Into the Unknown?: Table 1.
- (2015) Patrick Peter John Phillips et al. CLINICAL INFECTIOUS DISEASES
- Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
- (2015) Scott R. Evans et al. CLINICAL INFECTIOUS DISEASES
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Too much medicine: the challenge of finding common ground
- (2015) H. Macdonald et al. BMJ-British Medical Journal
- Too much medicine: the challenge of finding common ground
- (2015) H. Macdonald et al. BMJ-British Medical Journal
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Redefining the primary objective of phase I oncology trials
- (2014) Mark J. Ratain Nature Reviews Clinical Oncology
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Tolerance: Central and Peripheral
- (2012) Y. Xing et al. Cold Spring Harbor Perspectives in Biology
- Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Striking a balance between idealism and fatalism
- (2011) David Collingridge LANCET ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More